Skip to main content
Xencor Inc logo

Xencor Inc — Investor Relations & Filings

Ticker · XNCR ISIN · US98401F1057 LEI · 549300V5IF65437JKG30 US Manufacturing
Filings indexed 829 across all filing types
Latest filing 2025-06-16 Director's Dealing
Country US United States of America
Listing US XNCR

About Xencor Inc

https://xencor.com/

Xencor Inc. is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibody and cytokine therapeutics. The company's proprietary XmAb® protein engineering platform is used to create novel drug candidates with enhanced functionality, stability, and extended half-life for the treatment of cancer and autoimmune diseases. This technology enables the development of various therapeutic modalities, including bispecific antibodies designed to engage multiple targets simultaneously. Xencor is advancing a broad pipeline of candidates, with numerous programs in clinical testing, and its technology is utilized in several medicines marketed by partners.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2025-06-16 English
PRIMARY DOCUMENT
Director's Dealing
2025-06-16 English
PRIMARY DOCUMENT
Director's Dealing
2025-06-16 English
PRIMARY DOCUMENT
Director's Dealing
2025-06-16 English
PRIMARY DOCUMENT
Director's Dealing
2025-06-16 English
PRIMARY DOCUMENT
Director's Dealing
2025-06-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.